Intercept to Sell Ocaliva in PBC in Markets Outside U.S. for up to $450M

 Agreement includes rights for Advanz to commercialize orphan drug Ocaliva® for PBC outside the U.S., as well as the transition to Advanz of the international commercial and medical infrastructure of Intercept

Additionally, Intercept will receive royalties on any future ex-U.S. net sales of obeticholic acid in NASH

Intercept to discuss further details during Q1 2022 earnings call on Friday, May 6th at 8:30 a.m. ET

The conference call on Friday, May 6, will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com or by calling (855) 232-3919 (toll-free) with passcode 7738727. Archived webcasts will be available on Intercept’s website for approximately two weeks.

https://finance.yahoo.com/news/intercept-announces-advanz-pharma-acquire-111700177.html